Egnyte commissioned GatePoint Research to query 152 executives in Regulatory Affairs, R&D, Clinical and Quality about the challenges facing data-driven, mission-critical companies as they try to maintain GxP compliance, specifically around data integrity and data privacy and security.
The report looks at how the biotechs efficiently and securely manage collaboration and data and unveils some interesting results. One of the findings is that the most popular applications used to manage regulated data are not designed for life sciences specifically. In such a specialized field, this can lead to trouble.
Another finding the report points to is a divide developing amongst life scenes organizations. There are technology adopters and there are organizations that still operate from manual processes leading to friction in collaborating with partners and difficulty maintaining compliance with regulations.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.